Abstract: A method of preventing or reducing the incidence of post-operative adhesions in or associated with a body cavity, which comprises introducing into the body cavity a composition containing an aqueous solution or suspension or gel formulation containing the polysaccharide dextrin.

Abstract: The invention is directed to isolated polypeptides bearing sequence homology to the Sp36 protein found in pneumococcal organisms, such as Streptococcus pneumoniae. Polynucleotides encoding such polypeptides are also disclosed. The invention also relates to antibodies specific for the disclosed polypeptides and to uses of such antibodies in the treatment of diseases caused by staphylococci as well as group A and B streptococci. In addition, the invention relates to the use of the disclosed polypeptides in compositions and as vaccines and for prophylactic uses such as in vaccination of animals, especially humans, against a wide variety of streptococcal, staphylococcal and other diseases.

Abstract: High throughput screening assays for the identification of potential therapeutic agents able to modulate the activity of enzymes of fatty acid biosynthesis, especially desaturases and/or elongases, are disclosed along with therapeutic uses of the agents identified by such assays for the prevention and/or treatment of diseases related to fatty acid metabolism. Substrates useful in such assays are also described.

Abstract: A vehicle seat comprises a seat squab supported on a base structure, and a spring arrangement for weight adjustment, the spring arrangement being connected to a weight adjustment actuating device. Associated with the actuating device is a level indicator device for indicating adjustment of the seat squab to the seat squab level which optimally corresponds to the weight of the respective seat occupant, in relation to the spring travel of the seat squab. The level indicator device and the actuating device are provided at least substantially centrally at the front edge of the seat squab for optimum actuability and adjustability.

Abstract: Compounds of the general structure according to Formula (I) wherein R1 is selected from alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, and heterocycloalkyl; R2 is selected from alkyl, alkenyl, alkyny, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl; R3 is selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; W is selected from Ch2, O and S; n is 0 to about 3: X is selected from S or O; Y, if present, is selected from a bond, aryl, NH, NR, O or S, where R3 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl; and Z, if present, can represent a bond or is selected from lower alkyl, O or S are disclosed. Also disclosed are uses of such compounds for treating a variety of disease conditions, including cancer.

Abstract: A shaped sintered fibrous porous body exhibits a structure with a three-dimensional corrugated or undulating shape and porosity.

Abstract: In one aspect, the present invention provides an inhaler apparatus comprising interior surfaces having contact with a medicament for inhalation, the interior surfaces including an interior surface of a mouthpiece and a substrate with medicament deposited thereon, at least one of such interior surfaces comprising indentations or raised areas therein, the raised areas having valleys therebetween. In certain preferred embodiments, the interior surface is a surface on a substrate having medicament deposited thereon, and in other preferred embodiments, the interior surface is an interior surface of the mouthpiece of the inhaler. In addition to providing surface topology for minimizing the area of contact between the medicament and the surfaces of the inhaler, the surfaces are preferably made of a material having a low surface energy, and more preferably, also having, when uncharged, no substantial van der Waals or electrostatic interaction with the medicament.

Abstract: Provided is a powder delivery system which uses mechanical or electrical means to individually release covers that cover powder at a variety of powder aliquot locations on a rigid substrate.

Abstract: Disclosed is a human is a hTopI-.alpha. polypeptide and DNA (RNA) encoding such hTopI-.alpha. polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonists against such polypeptide. Also provided are methods of using the antibodies and antagonist inhibitors to inhibit the action of hTopI-.alpha. for therapeutic purposes such as an antitumor agent, to detect an autoimmune disease, or retroviral infections and to treat adenocarcinoma of the colon. Diagnostic methods for detecting mutations in the coding sequence and alterations in the concentration of the polypeptides in a sample derived from a host are also disclosed.

Abstract: Human UCE 7, UCE 8 and UCE 9 polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods of utilizing such polypeptide for the treatment of the proliferation of malignant cells. Antagonists against such polypeptides and their uses as a therapeutic to treat Alzheimer's disease, atrophying skeletal muscle, African swine fever virus and apoptotic cell death are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in UCE 7, 8 and 9 nucleic acid sequences and the concentration of polypeptides encoded by such sequences.

Abstract: A vaccine for protection against swine dysentery which comprises T. hyodysenteriae hemolysin and a physiologically acceptable vehicle for said peptide. The vaccine contains the hemolysin in an amount effective for protecting against swine dysentery. The invention also relates to a method of protecting swine against swine dysentery by administering to swine the vaccine described above.

Abstract: In a process and apparatus for the production of a component including a support element and foam portions adhering to the top and bottom surfaces thereof, the support element is arranged with its bottom surface over a first mold cavity of a mold. A cover is then sealingly fixed on the mold in such a way that a second mold cavity is defined between the cover and the support element. A first reaction mixture is introduced into the second mold cavity and reacts to form a first foam portion on the top surface of the support element. The cover with support element and first foam portion are then removed from the first mold cavity. Thereupon a second reaction mixture is introduced into the first mold cavity which is then immediately sealingly closed again by the unit consisting of the cover and the support element with its first foam portion.

Abstract: Dienes and/or acetylene impurities in an olefin feed; in particular a propylene feed, may be selectively hydrogenated in a single stage by use of a catalyst of palladium supported on alumina which is substantially crystalline alpha alumina, wherein the average pore radius is 200-2000 .ANG., with a least 80% of the pores having a pore radius within the range of 100 to 3000 .ANG.. The surface acidity of the catalyst is generally from 0.002 to 0.05 millimole of pyridine absorbed per gram of catalyst. The active palladium surface area is from 20 to 200 m.sup.2 /g. The palladium is in the form of crystallines having an average size of at least 25 .ANG..

Abstract: A process for oxidizing a hydrocarbon to maleic anhydride using a mixed oxide catalyst of vanadium and phosphorous prepared by a procedure including pretreating the dried catalyst precursor of the said mixed oxides in finely divided form with an acid solution.

Abstract: .[.In a hydrogenation operation employing an ebullated catalytic bed, recycle is recovered from the hydrogenated product with at least 25%, by volume, of the recycle boiling above 950.degree. F. The recycle is cooled to a temperature of from 350.degree. to 600.degree. F. to separate coke precursors, prior to recycle to the hydrogenation. Higher conversion levels can be achieved by effecting recycle in such manner..]..Iadd.Disclosed is a hydrogenation process using at least one fluidized catalytic stage and a recycle material of heavy hydrogenated effluent. The heavy effluent material is cooled to a temperature within 350.degree.-600.degree. F. to separate toluene and heptane insoluble coke precursors prior to recycle. This separation may be enhanced by the use of centrifugation, filtration or a bed of particulate material (e.g. calcined coke). .Iaddend.